PAR 5.00% 19.0¢ paradigm biopharmaceuticals limited..

New Player, page-79

  1. 648 Posts.
    lightbulb Created with Sketch. 334
    The tablet form is an approved drug Elmiron it is for bladder cysts, iPPS is injectable form of the same drug, and not intra venously but subcutaneous, which is easier and self administrable. Elmiron is the subject of thousands of law suits because it causes Macular degeneration if taken for a long time and at much higher doses than Zilosul.

    Zilosul was apparently in a phase three trial back in late 2022 but now not sure. Apparently FDA is bamboozled by the outcome and can't figure out WTF is going on and issued a please explain, apparently Par explained but has yet to receive a tick to proceed with a phase III which is funny because it was in a phase III but when law suits start all bets off, cross the T' s dot the I's so we wait & wait and the $ burns.

 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.